These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 32507818)

  • 1. [Multiple myeloma: a focus on drugs under development].
    Sunami K
    Rinsho Ketsueki; 2020; 61(5):520-527. PubMed ID: 32507818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
    Davis JA; Shockley A; Hashmi H
    J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma.
    Midha S; Hartley-Brown MA; Mo CC; Hossain S; Nadeem O; O'Donnell EK; Bianchi G; Sperling AS; Laubach JP; Richardson PG
    Expert Opin Drug Saf; 2023; 22(11):1049-1071. PubMed ID: 37906232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.
    Offidani M; Corvatta L; Morè S; Olivieri A
    Drug Des Devel Ther; 2021; 15():2401-2415. PubMed ID: 34103900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance.
    De Novellis D; Fontana R; Giudice V; Serio B; Selleri C
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor.
    Joseph NS; Tai YT; Anderson KC; Lonial S
    Clin Pharmacol; 2021; 13():169-180. PubMed ID: 34434061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma.
    Martino M; Paviglianiti A
    Expert Opin Biol Ther; 2021 Aug; 21(8):1025-1034. PubMed ID: 33412948
    [No Abstract]   [Full Text] [Related]  

  • 10. Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma.
    De Luca F; Allegra A; Di Chio C; Previti S; Zappalà M; Ettari R
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies.
    Sanchez L; Dardac A; Madduri D; Richard S; Richter J
    Ther Adv Hematol; 2021; 12():2040620721989585. PubMed ID: 33796236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
    Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Lendvai N; Sborov D; Suvannasankha A; Weisel K; Karlin L; Libby E; Arnulf B; Facon T; Hulin C; Kortüm KM; Rodríguez-Otero P; Usmani SZ; Hari P; Baz R; Quach H; Moreau P; Voorhees PM; Gupta I; Hoos A; Zhi E; Baron J; Piontek T; Lewis E; Jewell RC; Dettman EJ; Popat R; Esposti SD; Opalinska J; Richardson P; Cohen AD
    Lancet Oncol; 2020 Feb; 21(2):207-221. PubMed ID: 31859245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Management of Triple-Class Refractory Multiple Myeloma: A Review of Current Strategies and Emerging Therapies.
    Stalker ME; Mark TM
    Curr Oncol; 2022 Jun; 29(7):4464-4477. PubMed ID: 35877215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Optimization of treatment strategy for relapsed or refractory multiple myeloma].
    Ito S
    Rinsho Ketsueki; 2023; 64(9):1074-1082. PubMed ID: 37899185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Biological Therapies for Multiple Myeloma.
    Garfall AL
    Annu Rev Med; 2024 Jan; 75():13-29. PubMed ID: 37729027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New and emerging pharmacotherapies for the management of multiple myeloma.
    Moore DC; Oxencis CJ; Shank BR
    Am J Health Syst Pharm; 2022 Jul; 79(14):1137-1145. PubMed ID: 35333922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Belantamab mafodotin for the treatment of multiple myeloma.
    Wang B; Wu C; Zhong Q; Ling L; Wu Z; Yu B; Gao X; Zeng H; Yang DH
    Drugs Today (Barc); 2021 Nov; 57(11):653-663. PubMed ID: 34821879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity management strategies for next-generation novel therapeutics in multiple myeloma.
    Steinbach M; Julian K; McClune B; Sborov DW
    Ther Adv Hematol; 2022; 13():20406207221100659. PubMed ID: 35860442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment horizon in multiple myeloma.
    Soekojo CY; Chng WJ
    Eur J Haematol; 2022 Nov; 109(5):425-440. PubMed ID: 35880395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment.
    Lapietra G; Fazio F; Petrucci MT
    Biomolecules; 2022 Aug; 12(8):. PubMed ID: 36009041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.